Myo-inositol in assisted reproductive technology from bench to bedside.

D-chiro-inositol assisted reproductive technology in vitro fertilization infertility myo-inositol polycystic ovary syndrome

Journal

Trends in endocrinology and metabolism: TEM
ISSN: 1879-3061
Titre abrégé: Trends Endocrinol Metab
Pays: United States
ID NLM: 9001516

Informations de publication

Date de publication:
01 2024
Historique:
received: 05 05 2023
revised: 14 09 2023
accepted: 15 09 2023
medline: 11 1 2024
pubmed: 6 10 2023
entrez: 5 10 2023
Statut: ppublish

Résumé

Inositols are insulin-sensitizing compounds of promising efficacy in the management of polycystic ovary syndrome (PCOS). On the one hand, myo-inositol (myo-ins) plays a regulatory role in male and female reproductive function, influencing the development of oocytes, spermatozoa, and embryos. On the other hand, high concentrations of D-chiro-inositol (D-chiro-ins) in the ovary may adversely affect oocyte quality. This review analyses the available literature, which encourages the clinical use of myo-ins in assisted reproductive technologies (ARTs) due to its beneficial effects on female and male reproduction.

Identifiants

pubmed: 37798243
pii: S1043-2760(23)00194-7
doi: 10.1016/j.tem.2023.09.005
pii:
doi:

Substances chimiques

Inositol 4L6452S749
Insulin 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

74-83

Informations de copyright

Copyright © 2023 Elsevier Ltd. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of interests V.U. is employed at Lo.Li. Pharma Srl, Rome, Italy. All other authors have nothing to declare.

Auteurs

Andrea Etrusco (A)

Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (PROMISE), University of Palermo, Palermo, Italy; Unit of Obstetrics and Gynecology, 'Paolo Giaccone' Hospital, Palermo, Italy.

Antonio Simone Laganà (AS)

Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (PROMISE), University of Palermo, Palermo, Italy; Unit of Obstetrics and Gynecology, 'Paolo Giaccone' Hospital, Palermo, Italy; The Experts Group on Inositol in Basic and Clinical Research (EGOI).

Vito Chiantera (V)

Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (PROMISE), University of Palermo, Palermo, Italy; Unit of Gynecologic Oncology, National Cancer Institute - IRCCS - Fondazione 'G. Pascale', Naples, Italy.

Giovanni Buzzaccarini (G)

Obstetrics and Gynaecology Unit, IRCCS San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy.

Vittorio Unfer (V)

The Experts Group on Inositol in Basic and Clinical Research (EGOI); UniCamillus-Saint Camillus International University of Health Sciences, 00131 Rome, Italy. Electronic address: vunfer@gmail.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH